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The purpose of this research is to advance development of a photochemical tool 
designed to probe the role of ionotropic glutamate receptor signaling in 
neurodegenerative processes, and to delve more deeply into the biological processes 
underlying the role of these receptors in signaling and memory formation. This ligand-
targeted nanoprobe was designed and developed in our lab to label endogenous 
calcium-permeable AMPARs (CP-AMPARs) in live cells with minimal disruption to 
native receptor activity. Nanoprobe is designed to use naphthyl acetyl spermine 
(NASPM) as a photocleavable ligand to target and covalently label native CP-
AMPARs with a non-perturbing, fluorescent marker that then allows observation of 
these receptors using standard epifluorescence microscopy.  My contribution to this 
work, outlined in the aims below, is the characterization of nanoprobe using 
electrophysiology and fluorescent imaging to evaluate its effectiveness as an 





Aim 1: To use whole cell patch clamp electrophysiology to test the labeling of CP-
AMPARs with nanoprobe by recording changes in glutamate-evoked current through 
heterologously expressed GluA1-L497Y homomultimers during, pre- and post- 
nanoprobe labeling. 
  
Aim 2: To use fluorescent imaging to evaluate nanoprobe labeling of glutamate 
receptors endogenously expressed in hippocampal neurons by co-labeling nanoprobe-
treated neurons with traditional antibodies to AMPAR and synaptic targets.  
 
Aim 3: To use nanoprobe to detect endogenously expressed CP-AMPARs on live 
neurons during the course of neuron development. Live neuronal cultures will be 
imaged before and after labeling with nanoprobe in young dissociated cultures (DIV 
1-2) and in maturing cultures (DIV 14-17). 
 
Conclusions: Whole cell patch clamp electrophysiology results provide evidence that 
nanoprobe will label CP-AMPARs in a minimally-perturbing fashion that allows the 
receptors to resume normal activity after photolytic-release of ligand as designed. 
Fixed cell imaging of CP-AMPAR nanoprobe labeling was largely ineffective, and live 
cell imaging was not conclusive, but provided supporting evidence that nanoprobe 
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Normal communication in a healthy nervous system requires rapid transmission of 
information between neurons. This inter-neuronal communication is typically 
mediated chemically, via release of neurotransmitters into the synaptic cleft. One of 
the main neurotransmitters involved in this synaptic communication is glutamate, 
the primary excitatory neurotransmitter found in the central nervous system (CNS). 
The ionotropic glutamate receptors known as AMPA (2-amino-3-(5-methyl-3-oxo-1,2-
oxazol-4-yl)propanoic acid) receptors play a key role both in regulating excitatory 
signaling between neurons, and in long term potentiation (LTP), a type of synaptic 
plasticity thought to underlie memory formation. Malfunctions in ionotropic 
glutamatergic signaling due to alterations in mRNA editing, AMPAR trafficking and 
localization, or AMPAR channel kinetics can lead to destruction of synaptic spines and 
even of whole neurons. These destructive processes are implicated in a number of 
neurodegenerative disorders. While the majority of AMPARs allow only sodium ions 
to enter the post-synaptic neuron, calcium-permeable AMPA receptors (CP-AMPARs) 
allow calcium ions to enter as well, and thus have a unique role to play in disease 
processes and memory formation. CP-AMPARs have been implicated in the motor 
neuron loss that is the hallmark of the degenerative disease Amyotrophic Lateral 
Sclerosis (ALS), as well as in neuronal plasticity underlying processes involved in 





BACKGROUND AND SIGNIFICANCE 
Glutamate is the primary excitatory neurotransmitter in the CNS (central nervous 
system), and ionotropic glutamate receptors such as AMPA (amino-3-(5-methyl-3-oxo-
1,2-oxazol-4-yl)propanoic acid) receptors, kainate receptors, and NMDA (N-methyl-D-
aspartic acid) receptors play a key role in regulating excitatory signaling between 
neurons. Ionotropic glutamatergic signaling is critical to the synaptic plasticity 
underlying learning and memory, and malfunctions in this signaling can lead to 
destruction of synaptic spines and of whole neurons. These destructive processes are 
implicated in a number of neurodegenerative disorders.  
Ionotropic glutamate receptor architecture 
AMPARs, NMDARs, and kainate receptors, are all ionotropic glutamate receptors 
that share a number of structural similarities. Each functional receptor is composed 
of a tetramer of subunits that combine to create a central ligand-gated ion channel. 
Typically each receptor is composed of at least two different types of subunit per 
receptor, though AMPARs and kainate receptors can form homotetramers as well. 
There are four AMPAR subunits (GluA1-GluA4), five kainate receptor subunits 
(GluK1-GluK5), and 3 NMDA subunits (GluN1, GluN2 and GluN3). GluN2 and 
GluN3 subunits each have several subtypes of their own (GluN2A-D, and GluN3A-B). 
Each subunit has an intracellular carboxy-terminal tail (c-tail), a transmembrane 
region, and an extracellular region where glutamate and other agonists and 
antagonists can bind. The extracellular region consists of a ligand-binding domain, 
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and an amino-terminal domain which is involved in receptor formation, membrane 
targeting and trafficking, and in the case of NMDARs, regulation of signaling by 
binding allosteric modulators. The transmembrane region is primarily composed of 
four helices (M1, M2, M3, and M4) that line the ion channel pore, three of which 
completely span the membrane and one re-entrant loop that only partially spans the 
membrane (Traynelis et al., 2010).  Figure 1 illustrates these components with a 
cartoon of two AMPAR subunits in a phospholipid bilayer.  
The re-entrant loop of AMPAR subunits and kainate receptor subunits GluK1 and 
GluK2 contains a variable site (the Q/R site) which determines calcium permeability 
of the ion channel. When this site contains an uncharged glutamine (Q) for all four 
subunits, calcium ions can pass through the channel. However this neutral glutamine 
can be changed to a positively charged arginine through posttranscriptional mRNA 
editing, as is the case for the large majority of GluA2 subunits (Sobolevsky et al., 2009; 
Traynelis et al., 2010). This editing event results in functional channels that do not 
pass calcium. 
Typically AMPARs are composed of GluA1, 3, or 4 in combination with GluA2, causing 
the majority of AMPARs to be calcium-impermeable. When glutamate binds to 
calcium-impermeable AMPARs (CI-AMPARs) the intrinsic ion channel opens to allow 
monovalent cations, primarily sodium ions, to flow into the post-synaptic neuron and 
locally depolarize the membrane. However, a subset of AMPARs are calcium-
permeable, either because they lack the GluA2 subunit or because they include an 
unedited GluA2 subunit. When glutamate binds these calcium-permeable AMPARS 
(CP-AMPARs) the intrinsic ion channel opens and allows both sodium and calcium 
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ions to pass through the channel and into the post-synaptic neuron.  The regulation 
of calcium influx into synapses is critical to regulating activity-dependent synaptic 
plasticity, and ongoing research is demonstrating that these calcium-permeable 
AMPARs (CP-AMPARs) have a greater role in synaptic plasticity and neuronal 
development than was previously thought. 
Role of CP-AMPARs in synaptic development and neuronal 
plasticity 
Glutamate receptors are central to many of the mechanisms involved in neuronal 
adaptation and plasticity. In response to changes in neuronal activity these receptors 
can be added to, or removed from, synapses, and these activity-dependent 
modifications are thought to underlie many types of experience-dependent plasticity 
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including learning and memory formation. Long-term potentiation (LTP) and long-
term depression (LTD) are the two most ubiquitous and well-understood forms of this 
neuronal plasticity. Examples of both have been found at excitatory synapses 
throughout the brain. These synaptic modifications act to either strengthen the 
response of the post-synaptic neuron to excitatory signaling at that synapse (LTP), or 
to weaken the response (LTD). Both depend on calcium influx across the post-synaptic 
membrane, and both involve a number of synaptic modifications, including insertion 
(LTP) and removal (LTD) of AMPARs at the synapse (Kessels & Malinow, 2009; 
Luscher & Malenka, 2012; Malenka & Bear, 2004).  
The classic, most widely studied model of activity-dependent modification is NMDAR-
dependent LTP, which requires surface-expressed NMDA receptors to provide the 
channels through which calcium can influx into the neuron and trigger downstream 
plasticity (Bliss & Collingridge, 1993; Huganir & Nicoll, 2013; Malenka & Bear, 2004). 
However CP-AMPARs are also capable of providing the necessary route for calcium to 
enter neurons and trigger synaptic plasticity. Increasingly, researchers are finding 
examples of CP-AMPARs mediating activity-dependent synaptic modifications such 
as LTP and LTD, frequently in conjunction with signaling from other receptor types, 
such as group I metabotropic glutamate receptors (mGluRs) (Camire & Topolnik, 
2014; Hainmuller et al., 2014; Kullmann & Lamsa, 2008; Le Duigou & Kullmann, 
2011) or nicotinic acetylcholine receptors (nAChRs) (Griguoli et al., 2013).  
Often the described examples of CP-AMPAR-mediated LTP are specifically examples 
of ‘anti-Hebbian’ LTP, which requires simultaneous pre-synaptic glutamate release 
and post-synaptic hyperpolarization (Lamsa et al., 2007; Le Duigou & Kullmann, 
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2011; Le Roux et al., 2013; Oren et al., 2009; Szabo et al., 2012). When the neuronal 
membrane is depolarized CP-AMPARs are blocked by endogenous intracellular 
polyamines, while at resting or hyperpolarized potentials the CP-AMPAR intrinsic ion 
channel is unblocked allowing calcium influx. This decrease of current through the 
receptors as the membrane is depolarized is described as inward rectification. The 
term ‘anti-Hebbian’ was coined to differentiate this process from classic ‘Hebbian’ 
LTP, which is NMDA-dependent and requires pre-synaptic glutamate release and 
post-synaptic depolarization. In Hebbian LTP the post-synaptic depolarization is 
necessary to repel the positively charged extracellular magnesium ions that typically 
block the NMDAR intrinsic ion channel at resting membrane potentials (Kullmann & 
Lamsa, 2007). Interestingly, some evidence suggests that anti-Hebbian LTP is pre-
synaptically expressed (Lamsa et al., 2007; Nicholson & Kullmann, 2014), although 
Le Roux et al. (2013) suggests that at least in the specific case of CA1 parvalbumin 
interneurons, only post-synaptic LTP is present. There has also been at least one 
demonstration of apparent Hebbian LTP mediated in part by CP-AMPARS 
(Hainmuller et al., 2014). In this example the patch pipette solution contained 
spermine to maintain CP-AMPAR inward rectification, avoiding Hebbian LTP due to 
lack of intracellular polyamine block during membrane depolarization. 
In young (2.5-4 weeks old) rodent models, aspiny GABAergic interneurons are one of 
the most well-established sites of CP-AMPAR expression and NMDAR-independent 
LTP (Nissen et al., 2010; Oren et al., 2009; Polepalli et al., 2010; Sambandan et al., 
2010; Szabo et al., 2012). One explanation for the prevalence of CP-AMPARs on aspiny 
neurons is that they may help make LTP and other forms of plasticity synapse-specific 
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in the absence of dendritic spines. The morphology of dendritic spines provides a 
physical means of compartmentalizing influxing calcium and downstream molecular 
components of plasticity, helping to keep synaptic alterations specific to the active 
synapses where calcium is entering (Bourne & Harris, 2008; Goldberg et al., 2003; 
Yuste & Denk, 1995). As aspiny neurons lack this morphological means of 
compartmentalizing calcium and downstream signaling cascades, the question arises 
as to how they participate in synapse-specific plasticity. There are a number of 
mechanisms that likely contribute to containment of plasticity-related signaling, 
including barriers to diffusion of calcium and other small molecules (Soler-Llavina & 
Sabatini, 2006) and the rapid removal of calcium via the calcium/sodium exchanger 
(Goldberg et al., 2003). The rapid kinetics of CP-AMPARs provide an additional means 
of biochemical compartmentalization, restricting calcium to microdomains at the 
synapse (Angulo et al., 1999; Goldberg et al., 2003; Laezza & Dingledine, 2011).  
There is also some evidence to suggest that CP-AMPARs can play a role in NMDAR-
dependent LTP, though this finding is controversial. Plant et al. (2006) found evidence 
that CP-AMPARs are transiently expressed shortly after LTP induction in pyramidal 
neurons of the hippocampal CA1 region, and are replaced with CI-AMPARs within 
the first half hour. The authors suggest that these CP-AMPARs help to stabilize LTP 
at the involved synapses. However, a follow-up study by Adesnik and Nicoll (2007) 
failed to find evidence of CP-AMPAR expression following LTP induction in these 
same neurons. Putting this apparent contradiction in a slightly different light, 
Mattison et al. (2014), found that spines on apical dendrites in CA1 pyramidal neurons 
appeared to have a population of CP-AMPARs, while spines on basal dendrites did 
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not. This implies it would be possible to find CP-AMPAR absence and involvement at 
synapses on the same neuron, depending on which dendrites were examined. Finally, 
Clem and Huganir (2010) found evidence that transient expression of CP-AMPARs on 
a slower time scale helps consolidate fear memories at thalamic inputs to the lateral 
amygdala. An increase in CP-AMPAR expression was detected hours after auditory 
fear conditioning in mice, and was gone after seven days. Removal of these CP-
AMPARs one day after conditioning via a reconsolidation update protocol was key to 
erasing these fear memories. Use of this same protocol on the seventh day following 
conditioning failed to erase the fear memory.  
CP-AMPAR expression levels during development 
CP-AMPARs are expressed at higher levels in developing brains than in adult brains, 
and a number of animal model studies have linked CP-AMPAR expression levels to 
neuronal development. While AMPARs in the adult CNS predominately contain the 
edited GluA2 subunit that makes them impermeable to calcium, a variety of young 
principal neurons express synaptic AMPARs lacking GluA2. The timing of the switch 
from GluA2-lacking to GluA2-expressing synaptic AMPARs varies according brain 
region and cell type. Within the rat somatosensory cortex layer 4 stellate cells appear 
to make this switch between postnatal days 7 and 8 (P7 and P8), while layer 2/3 
pyramidal cells make the switch between P12 and P14 (Brill & Huguenard, 2008), and 
layer 5 pyramidal cells switch around P16 (Kumar et al., 2002). At the synapses 
between mossy fiber cells and CA3 pyramidal cells in the hippocampus, Ho et al. 
(2007) observed a transition from a population of mixed CP-AMPARs and CI-AMPARs 
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to primarily CI-AMPARs between 2 and 3 weeks postnatal. A postnatal switch from 
CP-AMPARs to CI-AMPARs has also been found at rat inner hair cells (Eybalin et al., 
2004), and in the chicken forebrain (Migues et al., 2007), while in zebrafish Mauthner 
cells a change in AMPAR subunit composition appears to take place between 33 hours 
post-fertilization and 48 hours post-fertilization (Patten & Ali, 2007). 
Role of CP-AMPARS in injury and disease 
CP-AMPARs have been strongly implicated in the neurological damage caused by a 
variety of brain injuries and disease processes that cause excess release of glutamate, 
a reduction in glutamate reuptake, or both. Excess exposure to extracellular 
glutamate initiates a number of processes toxic to neurons, described collectively as 
excitotoxicity (Lau & Tymianski, 2010). One of the primary ways in which glutamate 
excitotoxicity does so much neuronal damage is via overactivation of glutamate 
receptors such as CP-AMPARs, allowing extensive influx and accumulation of positive 
ions in the cytosol and overwhelming the neuron’s ability to remove these ions and 
repolarize the neuronal membrane. Cytosolic overloads of calcium have been found to 
be particularly toxic, though despite extensive research all of the complex mechanisms 
responsible for this toxicity have yet to be elucidated. While glutamate-induced 
increases in postsynaptic calcium play a critical role in the molecular processes 
thought to underlie memory formation and maintenance, the concentration of calcium 
ions and time-course of ion influx must be tightly controlled. Excess calcium appears 
to initiate a number of intracellular cascades resulting in neurotoxic outcomes that 
cause cell death via apoptosis or necrosis. These include the generation of nitric oxide, 
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activation of calcium-sensitive proteases such as calpains, and uptake of calcium into 
mitochondria leading to generation of reactive oxygen species and release of apoptotic 
mediators such as cytochrome C, which can lead to activation of caspase cell-death 
pathways (Lau & Tymianski, 2010; Orrenius et al., 2003; Szydlowska & Tymianski, 
2010; Weilinger et al., 2013). More recently, overload of cytosolic zinc ions has also 
been found to play a similar role in inducing excitotoxic cell death, often contributing 
to necrosis or apoptosis via the same pathways as calcium ions. CP-AMPARs are 
permeable to both zinc and calcium, meaning that their overactivation during 
excitotoxicity can contribute greatly to overload of cytosolic zinc and calcium, and 
consequent cell death (Kwak & Weiss, 2006; Sensi et al., 2009).  
CP-AMPAR-linked excitotoxic damage appears to be at least partially responsible for 
the neuronal death and neurological deficits caused by oxygen- and nutrient-
deprivation in the brain following a stroke, a heart attack or other ischemic event. 
Cerebral ischemia, the loss of blood flow to a portion of the brain, deprives neuronal 
tissue of the necessary oxygen and glucose to support neuronal function, leading to an 
increase in glutamate release into the extracellular space (Beppu et al., 2014; Davalos 
et al., 2000; Lau & Tymianski, 2010). Blockage or compression of blood vessels caused 
by a stroke or other trauma can cut off blood to a small or large portion of the brain, 
called focal ischemia, while global cerebral ischemia occurs when blood flow to the 
whole brain is cut off. Typically this happens during cardiac arrest or near drowning. 
Pyramidal neurons of the hippocampal CA1 region are particularly susceptible to the 
damage caused by the excess glutamate released during forebrain or global cerebral 
ischemia, selectively degenerating and then dying after a delay of several days. 
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Evidence suggests this is in part linked to an increase in CP-AMPAR expression which 
makes the neurons more vulnerable to the excess extracellular glutamate. In the wake 
of global or forebrain ischemic insult, GluA2 expression is downregulated in the 
pyramidal CA1 neurons of the hippocampus, and there is an increase in inwardly 
rectifying excitatory postsynaptic currents (EPSCs) that can be blocked by NASPM. 
Furthermore, NASPM injected into the hippocampus after ischemic insult can 
partially protect the CA1 neurons from death (Kwak & Weiss, 2006; Lau & Tymianski, 
2010; Liu & Zukin, 2007; Noh et al., 2005). There is also evidence to suggest that 
seizure or hypoxia-induced expression of CP-AMPARs may be involved in the 
pathogenesis of some epileptic conditions, possibly dependent on the stage of brain 
development during which the initial trauma occurred (Cull-Candy et al., 2006; H. C. 
Prince et al., 2000; H. K. Prince et al., 1995). 
CP-AMPARs may significantly contribute to neurodegeneration in amyotrophic 
lateral sclerosis (ALS), a currently incurable disease in which progressive motor 
neuron degeneration leads to loss of muscle strength and control, paralysis, and 
eventual death. Some forms of ALS, known as familial ALS (fALS), run in families 
and in some cases are linked to known genetic mutations. However, the vast majority 
of cases are sporadic ALS (sALS), which arises in someone with no known family 
history of ALS, and in which there is often no genetic link yet identified. Despite 
intensive, ongoing research, the mechanisms and triggers underlying disease 
pathogenesis are still not well understood. Over twenty different mutations have been 
linked to fALS, and these account for only about half of fALS cases and very few sALS 
cases. Given the number of genetic and environmental factors already implicated in 
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disease progression and the heterogeneity of ALS clinical presentation, it is likely that 
different molecular pathways have greater or lesser importance as causative factors 
in the disease pathogenesis of different patient subgroups. Research to-date suggests 
ALS neurodegeneration is a complex interaction between genetic and molecular 
pathways, involving mechanisms that include mitochondrial dysfunction, oxidative 
stress, protein aggregation in the cytoplasm, and glutamate excitotoxicity (Kiernan et 
al., 2011; Shaw, 2005; Yamashita & Kwak, 2014). 
Excitotoxicity has long been suspected as a mechanism in ALS motor neuron death 
due to the particular vulnerability of motor neurons to AMPA-mediated signaling in 
spinal cord culture (Kawahara et al., 2003). Initially, much research focused on the 
question of whether GluA2 expression was downregulated in ALS motorneurons, as 
that would imply the presence of CP-AMPARs and help explain the vulnerability to 
AMPAR-mediated excitotoxicity. Although results were mixed, the weight of the 
evidence suggested that the GluA2 subunit is present in these neurons, meaning that 
if CP-AMPARs are overexpressed it is likely not due to a lack of GluA2 (Kawahara et 
al., 2003; Vandenberghe et al., 2000). Consequently, Kawahara et al. (2004) turned 
their attention to investigating the role of GluA2 editing in ALS. Looking at motor 
neurons from five sALS patients they found evidence of reduced GluA2 mRNA editing 
efficiency, which suggests that CP-AMPARs might indeed be responsible for some 
excitotoxic motor neuron damage in ALS, but rather than lacking GluA2 these 
receptors could be incorporating unedited GluA2.  
Hideyama et al. (2012) pursued the question of ALS motor neuron excitotoxicity due 
to impaired GluA2 editing on a somewhat larger scale, using spinal cord tissue and 
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motor neurons from 29 ALS patients who encompassed several different ALS 
phenotypes. To determine if GluA2 editing is different in ALS motor neurons versus 
motor neurons from control subjects they measured expression levels of ADAR2, the 
enzyme responsible for removing AMPAR calcium permeability via an edit to the 
mRNA of the GluA2 subunit at the Q/R site of the re-entrant loop of the M2 membrane 
region. They found that ADAR2 was downregulated in these neurons, and as might 
be expected, this downregulation correlated with a reduction in editing efficiency of 
GluA2 mRNA. This bolsters the suggestion that increased CP-AMPAR expression 
may indeed be leading to excitotoxic death of motor neurons in many ALS cases of 
differing phenotypes. Furthermore, loss of ADAR2 activity in a motor neuron selective 
conditional knock-out mouse was found to lead to the slow death and degeneration of 
motor neurons, which could be rescued by a expressing edited GluA2 (Hideyama et 
al., 2010). Interestingly, in the ADAR2-lacking motor neurons of these mice, the 
protein TDP-43 is found cleaved and aggregated in cytoplasmic inclusions. This 
pathology is a hallmark of ALS and is found in the majority of ALS cases, further 
implicating ADAR2 downregulation in ALS pathophysiology (Yamashita & Kwak, 
2014). The clinical and therapeutic importance of understanding the role of CP-
AMPARs and excitotoxicity in ALS is highlighted by the fact that the only drug that 
has had even very moderate success at slowing disease progression is riluzole, a drug 
that inhibits glutamate release (Zinman & Cudkowicz, 2011).  
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Role of CP-AMPARS in drug addiction  
Animal model studies implicate CP-AMPARs in the neuronal plasticity underlying 
drug addiction. In response to drug exposure, CP-AMPAR levels have been found to 
increase in the ventral tegmental area (VTA) and the nucleus accumbens (NAc), two 
regions of the brain involved in motivation and reward circuitry (Wolf & Tseng, 2012). 
The increased receptor expression levels follow different time scales in the two 
regions, with an immediate response in the VTA. Saal et al. (2003) found that cocaine, 
amphetamine, nicotine, morphine and ethanol all increased excitatory synaptic input 
onto dopaminergic (DA) neurons of the VTA twenty-four hours after a single injection 
of the drug in question. Further research links this increase to the insertion of CP-
AMPARs into the excitatory synapses onto DA neurons. A variety of cocaine exposure 
paradigms, including a single injection of the drug, have been shown to boost insertion 
of CP-AMPARs into the synapses of DA neurons of the VTA within twenty-four hours 
of drug administration in mice (Bellone & Luscher, 2006; Mameli et al., 2007) and rats 
(Argilli et al., 2008; Borgland et al., 2004). While this increase lasted only days 
following intraperitoneal injection regimens, a two-week self-administration regimen 
led to a potentiation of excitatory synapses onto the VTA that could still be detected 
months after withdrawal (Chen et al., 2008).  
Elevated levels of calcium-permeable AMPARs are also detectable in the medium 
spiny neurons of the NAc during withdrawal from self-administered cocaine. In 
contrast to the VTA response, CP-AMPAR levels do not detectably increase in the NAc 
until several weeks after the start of withdrawal (Conrad et al., 2008; Mameli et al., 
2009). At this point in withdrawal CP-AMPARs in the NAc appear to be involved in 
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mediating cue-induced cocaine cravings, which are frequently the cause of relapse for 
recovering addicts (Pickens et al., 2011). This avenue of research suggests that CP-
AMPARs offer a potential druggable target to help recovering addicts avoid relapses. 
In an animal model, both directly blocking CP-AMPAR transmission (Conrad et al., 
2008) and preventing CP-AMPAR accumulation during withdrawal (Loweth et al., 
2014) reduced cocaine-seeking behavior. 
Use of endogenous polyamines and neurotoxins to target CP-
AMPARs 
A number of polyamine-containing neurotoxins found in insect venoms have some 
degree of selectivity for CP-AMPARs, and synthetic analogues of these toxins have 
provided a means for pharmacologically distinguishing subtypes of ionotropic 
glutamate receptors. Polyamines are small molecules that play an interesting and 
varied role in eukaryotic cellular biology, and have been found to be involved in 
regulating a number of cellular functions including cell growth and death, protein 
synthesis, and signaling through ion channels in the cell membrane (Li et al., 2007; 
Stromgaard & Mellor, 2004). The endogenous polyamines spermine and spermidine 
are known to interact with several ionotropic glutamate receptors including AMPARs, 
kainate receptors, and NMDARs.  
These polyamines block active CP-AMPARs and calcium-permeable kainate receptors 
(CP-KARs) when applied extracellularly (Washburn & Dingledine, 1996), and block 
them intracellularly as well, in a voltage-dependent fashion. This intracellular block 
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is in fact responsible for the inwardly-rectifying property of CP-AMPARs and CP-
KARs. As the neuronal membrane depolarizes, intracellular polyamines block the ion 
channel, preventing cations from flowing down their concentration gradient and out 
of the cell (Bowie & Mayer, 1995; Stromgaard & Mellor, 2004). This polyamine 
blockage is possible due to the presence of the glutamine, as opposed to the positively 
charged arginine, at the Q/R site in the re-entrant loop of the M2 membrane region of 
CP-AMPARs and CP-KARs. While endogenous spermine has been shown to potentiate 
both NMDA receptors (Mony et al., 2009) and kainate receptors (Mott et al., 2003), 
this interaction most likely revolves around spermine stabilization of either the 
amino-terminal domain interface or the ligand-binding domain interface, rather than 
the open channel-block which is the defining interaction between ionotropic receptors 
and  the polyamine toxins.  
Polyamine toxins found in spider and wasp venoms exploit one aspect of this open-
channel blocking interaction with ion channels, but instead of normal ion channel 
regulation these toxins can block some channels completely, leading to paralysis. The 
first polyamine toxin structure to be characterized was the orb weaver spider venom 
argiotoxin-636 (ArgTX-636), which was characterized in 1986. The structure of Joro 
spider toxin (JSTX-3) was next to be characterized, followed by a number of other 
spider toxins, as well as the Egyptian digger wasp venom philanthotoxin (PhTX-433). 
ArgTX-636, JSTX-3, PhTX-433, and PhTX-343 have been shown to act as open-
channel blockers that selectively bind to the intrinsic ion channel of glutamate-bound 
calcium-permeable AMPA and kainate receptors. That is, these toxins block receptors 
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that are in the process of receiving glutamatergic neurotransmission (Stromgaard & 
Mellor, 2004).  
The historical use of these polyamine toxins to target receptors with specificity is 
somewhat complex. The range of measured IC50 values for polyamine toxins applied 
to CP-AMPARs has generally been given as somewhere between 30 nM and 3 µM 
(Brackley et al., 1993; Jackson et al., 2011). However, molecules in this 
pharmacological class are also known to antagonize both NMDARs and nAChRs, 
particularly at higher concentrations, though reports on the potency of such 
compounds for these two receptor classes are very mixed. Some studies have even 
reported that certain polyamine toxins have similar IC50 values for both NMDARs and 
CP-AMPARs, typically in the nM to single µM range.  
This variability of IC50 values appears to be due to the employment of a range of 
experimental conditions, cell types, and the use of endogenous versus heterologous 
receptors, all of which affect the subunit make-up of the receptor, and hence 
sensitivity to polyamine toxins. An early study by Brackley et al. (1993) tested two 
different polyamine toxins on glutamate receptors, using two different approaches to 
receptor expression in Xenopus oocytes. They found that when rat brain RNA was 
injected into oocytes, for both non-NMDA glutamate receptors and NMDARs the IC50 
of ArgTx-636 was sub-micromolar. The IC50 of PhTx-343 for non-NMDA glutamate 
receptors was also sub-micromolar, while for NMDARs it was 2.5 µM. However, 
oocytes expressing only GluA1 RNA were much less sensitive to blockage by either 
polyamine, with both toxins producing an IC50 of around 3 µM. For oocytes injected 
with only NMDAR1, ArgTx-636 still had a sub-micromolar IC50, while PhTx-343 had 
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an IC50 over 2 µM. Oocytes expressing GluA1 and GluA2 together were essentially 
insensitive to blockage by either toxin, with both producing IC50s of around 300 µM. 
A later study also using whole rat brain RNA provided supporting evidence that non-
NMDA glutamate receptors are more sensitive to PhTx-343 than other possible 
targets. When receptors heterologously expressed in Xenopus oocytes were treated 
with the PhTX-343 at -80 mV, an IC50 of 0.46 µM was found for AMPARs, and an IC50 
of about 2 µM was found for NDMARs. An IC50 of approximately 16 µM was found for 
nAChRs, which were endogenously expressed on TE671 cells held at -100 mV. The 
selectivity for AMPARs was dramatically improved with the modified compound 
PhTX-83, which had an IC50 of 32 nM (Mellor et al., 2003; Stromgaard & Mellor, 2004). 
These somewhat mixed results are likely attributable to several factors, including the 
use of a heterologous expression system that appears to express endogenous 
glutamate receptor subunits capable of interacting with the heterologous subunits to 
some degree (Schmidt & Hollmann, 2008; Schmidt et al., 2009; Soloviev & Barnard, 
1997). Additionally, in the preceding examples kainate was used to activate non-
NMDA glutamate receptors prior to polyamine toxin block. Jackson et al. (2011) later 
found that philanthotoxin is much more effective at blocking CP-AMPARs treated 
with glutamate than those treated with kainate. They also found that the presence of 
transmembrane AMPAR regulatory proteins (TARPS) increases the potency of PhTx-
433 at blocking CP-AMPARs. This suggests that endogenous AMPARs expressed on 
neurons that also natively express TARP proteins will have more sensitivity to 
blockage by polyamine toxins than heterologously expressed recombinant AMPARs.  
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When testing polyamine toxin sensitivity on oocytes expressing whole rat brain RNA 
(Brackley et al., 1993; Mellor et al., 2003) or on cerebellar granule neurons (CGNs) 
from GluA2 knock-out mice (Jackson et al., 2011), CP-AMPARs were not 
pharmacologically isolated from CP-KARs. However in the CGNs CP-AMPARs likely 
heavily outnumbered CP-KARs, as the lack of GluA2 would make all AMPARs 
calcium-permeable, while kainate receptors were presumably present in normal ratios 
of calcium-permeable and impermeable receptors. In a paper that provides a more 
direct comparison of polyamine toxin effects on CP-AMPARs and CP-KARs, Bahring 
and Mayer (1998) studied the response of homomeric CP-KARs consisting of GluK2(Q) 
subunits (also known as GluR6(Q) subunits) and homomeric GluA1 CP-AMPARs to 
PhTX-343 block. While they found an IC50 of 60 nM at -60 mV for GluK2 homomers 
using domoic acid, they found GluA1 homomers to be even more sensitive to PhTX-
343 block. The GluA1 homomers were almost entirely blocked by 30 nM of the 
philanthotoxin at -60 mV, using glutamate as an agonist, suggesting that while both 
CP-KARs and CP-AMPARs are sensitive to philanthotoxin block under the correct 
conditions, CP-AMPARs are preferentially targeted. When Blaschke et al. (1993) 
treated CP-AMPARs or GluK2(Q) CP-KARs with 0.5 µM JSTX-3, they found both 
receptors ranged from 80% blocked to nearly 100% blocked. The relatively high dose 
of toxin used may have prevented differences in receptor sensitivity from being 
revealed. 
Naphthyl acetyl spermine (NASPM) was originally synthesized as an analogue of 
JSTX-3, to have more specificity for CP-AMPARs (Stromgaard & Mellor, 2004). While 
a few studies have used NASPM to target both CP-AMPARs and CP-KARs, in these 
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cases the authors used relatively high concentrations of 200 μM (Sun et al., 2009) to 
300 μM NASPM (Ogoshi & Weiss, 2003; Yin et al., 2002). Koike et al. (1997) found 
NASPM be a specific blocker of CP-AMPARs when tested on hippocampal neurons 
with a strong inwardly rectifying response to kainate and high calcium-permeability, 
due to expression of AMPARs containing only GluA1 and GluA4 subunits (Iino et al., 
1996). They found a NASPM IC50 of 0.33 µM at -60 mV for these neurons. In contrast, 
hippocampal neurons with a slight outwardly rectifying response to kainate and low 
calcium permeability were insensitive to NASPM block. Currently, NASPM is the de 
facto standard used as a CP-AMPAR-specific ligand (Camire & Topolnik, 2014; Gong 
et al., 2011; Hainmuller et al., 2014; Loweth et al., 2014; McCutcheon et al., 2011; 
Studniarczyk et al., 2013; White et al., 2015). For this reason, NASPM was selected 
to be the primary model for the targeting ligand of a novel nanoprobe designed and 
synthesized in the Chambers lab for the purpose of labeling endogenous CP-AMPARs 
in live neurons with a minimally perturbing, fluorescent tag.  
Nanoprobe for labeling CP-AMPARs 
The Chambers lab has developed a novel photocleavable nanoprobe (Figure 2) for 
labeling endogenous CP-AMPARs in live cells with minimal disruption to native 
receptor activity. This nanoprobe is a ligand-targeted molecular tag designed to 
covalently label native membrane-bound receptors with a non-perturbing, fluorescent 
marker that then allows observation of these receptors using standard epifluorescence 
microscopy. To achieve CP-AMPAR specificity, the ligand portion of the probe was 
designed to capitalize on the pharmacology of the polyamine toxin molecules Joro 
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spider toxin, argiotoxin, philanthotoxin-433 and, most structurally similar, the 
synthetic CP-AMPAR blocker NASPM (Brackley et al., 1993; Stromgaard et al., 1999; 
Stromgaard & Mellor, 2004; Yoneda et al., 2001). Once nanoprobe has been applied, 
the ligand can be cleaved, leaving only the fluorescent tag covalently-bound to the 
receptor (Vytla et al., 2011). As the nanoprobe requires no genetic manipulation and 
uses a small molecule dye as the fluorescent label, this system offers the opportunity 
to observe receptor location and activity without the potentially confounding effects of 
genetic overexpression or of labeling with a large macromolecule such as an antibody 
or fluorescent protein.  
Due to the NASPM-derived ligand, this tri-part nanoprobe is designed to be selective 
for active CP-AMPARs. After binding glutamate, the transmembrane helices move to 
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open the channel so that ions can pass through. When binding takes place, the ligand-
binding domain closes around the glutamate, and it is thought that this movement 
pulls the M3 helix up and away from each other, unblocking the channel (Dong & 
Zhou, 2011).  After the nanoprobe ligand has moved into the open channel (see Figure 
2), the electrophilic moiety on the nanoprobe is brought into close proximity with the 
surface of the receptor, making it possible for the electrophile to form a covalent bond 
with a nucleophilic amino acid on the surface of the receptor. Once that bond has 
formed the ligand can be cleaved using UV light, thus allowing the receptor to return 
to its normal, unbound state while leaving the fluorescent part of the probe bound to 





RESEARCH DESIGN AND METHODS 
Aim 1: Whole cell patch clamp electrophysiology  
The goal of aim 1 is to use whole cell patch clamp electrophysiology to test the labeling 
of CP-AMPARs with nanoprobe by recording changes in glutamate-evoked current 
through heterologously expressed GluA1-L497Y homomultimers during, pre- and 
post- nanoprobe labeling.  
To evaluate how nanoprobe interacts with CP-AMPARs, HEK293T cells will be 
transfected with GluA1-L497Y-pIRES2-eGFP cDNA using liposomal delivery. After 
the transfected HEK cells express GFP-tagged GluA1 homomers, glutamate-evoked 
current through these receptors will be recorded before and after nanoprobe 
treatment, allowing us to measure the effect of nanoprobe on CP-AMPAR function. 
HEK293T cells will be plated on glass coverslips treated with polylysine, grown at 5% 
C02 and 37 °C, and at 70% confluency cells will be transfected with bicistronic vector 
GluA1-L497Y-pIRES2-eGFP (Nagarajan et al., 2001). The GluA1-L497Y subunit is a 
non-desensitizing variant of the GluA1 subunit, used here to slow desensitization and 
facilitate data collection. AMPAR desensitization occurs after a period of ongoing 
agonist exposure, resulting in the closure of the intrinsic ion channel while agonist is 
still bound to the receptor (Gouaux, 2004; Mitchell & Fleck, 2007). By reducing 




One to three days post-transfection green cells will be located and then subjected to 
whole cell patch clamp electrophysiology. After washout of residual media, whole cell 
patch configuration will be established, holding cells at -70 mV. Extracellular solution 
(ECS) will be continuously perfused onto the coverslip unless otherwise noted, while 
drug compounds will be delivered to the patched cell by local perfusion, as in Figure 
4. 
 
A baseline glutamate response will first be measured by delivering three 1 second 
pulses of 20 μM glutamate, each delivered 1 minute apart. Next, ECS perfusion will 
be turned off as a combined solution of 20 μM glutamate and 1 μM nanoprobe is 
washed on for 1 min, after which ECS perfusion will be started up again. After 
washing the coverslip for 1 minute to remove residual nanoprobe and glutamate, a 1 
second pulse of 20 μM glutamate will be delivered to probe the ability of the GluA1 
channels to open in response to glutamate and allow ionic current to flux into the cell. 
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Fifteen seconds later, another 1 sec pulse of 20 μM glutamate will be delivered in 
combination with a 15 second exposure to 380 nm light, which should release the 
NASPM-derived ligand, unblocking the channels and restoring glutamate-evoked 
ionic current into the cell. Following ligand-release, three 1 second pulses of 20 μM 
glutamate will be delivered, each 1 minute apart to determine the average glutamate 
response post-treatment.  The peaks of the initial three glutamate responses that were 
recorded prior to treatment with nanoprobe will be averaged, and maxima of 
glutamate-evoked responses later in the experiment will be normalized to this average 
baseline response. Figures 5 and 6 illustrate the predicted glutamate-evoked current 











To evaluate the use-dependency of nanoprobe, these results will be compared to 
glutamate-evoked responses in cells treated with 1 μM of nanoprobe alone. In these 
control experiments the initial three pulses of 20 μM glutamate will be delivered to 
establish an average baseline response following the same protocol as used in the 
initial experiment. However, those three pulses will be followed by a 1 min application 
of 1 μM nanoprobe alone, rather than a combined treatment of glutamate and 
nanoprobe together. After treatment with nanoprobe alone, the protocol will be 




and the coverslip will be washed for 1 min, two pulses of glutamate will then be 
delivered 15 seconds apart, the second one accompanied by a 15 second exposure to 









Aim 2: Imaging co-labeled endogenous receptors  
The goal of aim 2 is to use fluorescent imaging to evaluate nanoprobe labeling of 
glutamate receptors endogenously expressed in hippocampal neurons by co-labeling 
nanoprobe-treated neurons with traditional antibodies to AMPAR and synaptic 
targets.  
To evaluate nanoprobe labeling of endogenous glutamate receptors, fluorescent 
imaging will be used to compare the locations of nanoprobe-labeled receptors to the 
locations of proteins labeled with synaptic and AMPAR antibodies. Primary 
dissociated hippocampal cultures will be prepared from embryonic day E18-E20 
Sprague-Dawley rat embryos. Hippocampi will be isolated, trypsinized and cultured 
for 14-24 days on polylysine-treated coverslips, grown in serum-containing medium at 
5% CO2 and 37 °C, and fed 200 uL of media about every five days.  All animal care 
and experimental protocols were approved by the Animal Care and Use Committee at 
University of Massachusetts Amherst, Amherst, MA, USA. 
As an initial step towards visualizing CP-AMPARs at active synapses via nanoprobe 
labeling of native neuronal receptors, coverslips of live dissociated hippocampal 
cultures will be imaged before and after treatment with nanoprobe. Coverslips will be 
washed with 3 times with ECS, imaged to establish background fluorescence, 
incubated with nanoprobe,  washed 3 more times with ECS and imaged again. 
After using live imaging experiments to develop initial treatment and imaging 
parameters for nanoprobe labeling of neurons, coverslips will be labeled with both 
nanoprobe and fluorescent antibodies to evaluate probe colocalization with synaptic 
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and AMPAR proteins. Dissociated hippocampal neurons will be treated with a range 
of nanoprobe concentrations, fixed, and stained with an antibody to either AMPA 
receptors generally, to GluA1 specifically, or to the synaptic protein synapsin. Anti-
AMPAR and anti-GluA1 will label both synaptic and extra-synaptic AMPARs, and 
synapsin will label synapses. 
To visualize nanoprobe colocalization with AMPA receptors, coverslips of dissociated 
hippocampal culture will be treated with either the polyclonal Santa Cruz Biotech 
pan-AMPAR antibody at 1:200 dilution or with the Millipore Anti-GluR1-NT RH 95 
monoclonal antibody at 1:1000 dilution. Coverslips will be washed with ECS three 
times, treated with nanoprobe, and fixed in 4% paraformaldehyde for at least 10 min. 
Following cell fixation, coverslips will be washed three times with PBS, and treated 
with permeabilizing or non-permeabilizing blocking buffer containing goat serum in 
preparation for labeling with primary antibody.   
Permeabilizing blocking buffer will be used during treatment with polyclonal pan-
AMPAR antibody to allow the antibody access to both extracellular and intracellular 
epitopes. Anti-GluA1 treated coverslips will be incubated with either permeabilizing 
or non-permeabilizing blocking buffer. The anti-GluA1 antibody targets the n-
terminus of the GluA1 subunit, which is located on the extracellular portion of the 
protein, so use of non-permeabilizing blocking buffer will label only GluA1-containing 
AMPARs that are still surface-expressed at the time of fixation. Use of permeabilizing 
blocking buffer will allow us to visualize both externally expressed and internalized 
GluA1 subunits.  
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After labeling with primary antibody coverslips will be washed with PBS and treated 
with secondary antibody. Anti-GluA1 coverslips will be treated with the Thermo 
Scientific Goat Anti-Mouse IgG Dylight 488 secondary antibody, while pan-AMPAR 
treated coverslips will be labeled with 488 DyLight goat anti-rabbit secondary 
antibody. Following antibody labeling coverslips will be washed again with PBS, 
dried, mounted with ProLong Gold antifade and sealed. 
To visualize nanoprobe colocalization with synapses, nanoprobe-treated coverslips 
will be labeled with the monoclonal antibody from Cell Signaling for the synaptic 
marker synapsin-1 (D12G5) XP, product number 5297. Dissociated hippocampal 
cultures will be washed with ECS three times and treated with nanoprobe. As with 
anti-GluA1 and pan-AMPAR treated cultures, coverslips will be fixed in 4% 
paraformaldehyde for at least 10 min, washed three times with PBS, and treated with 
permeabilizing blocking buffer containing goat serum in preparation for labeling with 
primary antibody.  After labeling with anti-synapsin-1, coverslips will be washed with 
PBS, treated with 488 DyLight goat anti-rabbit secondary antibody, and washed 
again with PBS. Following antibody labeling, coverslips will be dried, mounted with 
ProLong Gold antifade and sealed.  
To further evaluate nanoprobe specificity in labeling of native neuronal receptors, 
dissociated hippocampal cultures will also be treated with nanoprobe in combination 
with either 25uM of the non-NMDAR glutamate receptor antagonist DNQX, a 
stoichiometric concentration of non-liganded nanoprobe, or 20uM glutamate, prior to 
being fixed and stained with primary antibody. If nanoprobe is specifically targeting 
active CP-AMPARs, DNQX should reduce nanoprobe labeling while glutamate should 
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increase labeling and colocalization with anti-GluA1 or pan-AMPAR antibody. 
Treatments with non-liganded nanoprobe will allow us to visualize off-target labeling 
due to interactions of the nanoprobe electrophile with non-CP-AMPAR nucleophiles 
on the cell membrane. 
Aim 3: Imaging and tracking nanoprobe-labeled receptors 
on live neurons 
The goal of aim 3 is to use nanoprobe to detect endogenously expressed CP-AMPARs 
during the course of neuron development. Live neuronal cultures will be imaged before 
and after labeling with nanoprobe in young dissociated cultures (DIV 1-2) and in 
maturing cultures (DIV 14-17). 
To label and track the movement of endogenous CP-AMPARs of live hippocampal 
neurons, primary dissociated hippocampal cultures will be incubated with nanoprobe 
and imaged live using confocal fluorescent microscopy. Hippocampi will be isolated 
from embryonic day E18-E20 Sprague-Dawley rat embryos, trypsinized and cultured 
for either 1-2 days or 14-17 days on polylysine-treated coverslips, grown in serum-
containing medium at 5% CO2 and 37 °C, and fed 200 uL of media about every five 




Dose-dependent labeling of live neurons with nanoprobe 
Prior to imaging and tracking CP-AMPARs on live cells, the appropriate nanoprobe 
concentration for live labeling will be determined. During prior imaging experiments 
that primarily focused on fixed cell imaging, it was difficult to establish a consistently 
effective concentration. As previously mentioned, the reported IC50 values for this 
class of blockers range from 30 nM to 3 µM (Brackley et al., 1993; Jackson et al., 2011) 
and much of this variation seems attributable to differences in tissue culture and 
experimental conditions. Thus, during our live labeling experiments a similar range 
of nanoprobe concentrations will be tested to optimize labeling while attempting to 
maintain specificity.  
To determine the optimal nanoprobe concentration for use in labeling live cells, a 
range of concentrations from 100 nM to 3 μM will be tested on DIV 14-17 neurons. We 
chose 100 nM as our low concentration because previous experiments with 30 nM 
resulted in no detectable fluorescence accumulation. Coverslips will be washed 3 times 
with extracellular solution (ECS), imaged to establish background fluorescence, and 
then treated with 100 nM nanoprobe in ECS for 5 minutes. After this incubation 
period with a low concentration of nanoprobe, the coverslips will be gently washed 3 
times with ECS and imaged again. Finally, the same region of the coverslip will be 
used to assay a higher concentration of nanoprobe, independently either 300 nM, 1 
µM, or 3 µM in ECS. A 5 minute incubation in the higher concentration of nanoprobe 
will be followed by three washes with ECS prior to resuming imaging. Fluorescence 
intensity of tissue labeled at the higher probe concentration will be compared to 
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fluorescence intensity at the 100 nM concentration and both will be compared to 
background fluorescence prior to any labeling. 
Co-incubation with competitor molecules 
To test the specificity of nanoprobe for CP-AMPARs on live neurons, probe will be 
applied to DIV 14-17 neurons while co-treating the coverslips with the non-fluorescent 
competitor molecules NASPM or DNQX. Co-treatment with a stoichiometric 
concentration of NASPM will test for specificity to NASPM-sensitive targets, 
presumably primarily CP-AMPARs. As NASPM interacts with the CP-AMPAR ion 
channel pore of active receptors in the same way that the nanoprobe ligand is designed 
to interact with those ion channel pores, NASPM should prevent interaction between 
nanoprobe and CP-AMPARs. Co-treatment with 10 μM DNQX will test for specificity 
to AMPARs and kainite receptors, as DNQX blocks the glutamate-binding site of those 
receptors. Lack of glutamate-binding should prevent channel opening, thus also 
preventing nanoprobe interaction with the open CP-AMPAR ion channel. Together 
these co-incubations will help us determine if nanoprobe is indeed targeting NASPM-
sensitive glutamate receptors. 
To establish background fluorescence, each coverslip will be washed 3 times with ECS 
and imaged prior to any treatments with nanoprobe or competitor molecules. Each 
coverslip will then be simultaneously co-treated with 300 nM nanoprobe and a 
competitor molecule, washed 3 times with ECS, and imaged again. Finally, coverslips 
will be treated with 300 nM nanoprobe alone, washed 3 times with ECS and imaged. 
Fluorescence intensity of tissue labeled in the presence of nanoprobe alone will be 
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compared to the fluorescence intensity of the same location when treated with both 
nanoprobe and a competitor, and both will be compared to background fluorescence.  
To evaluate nanoprobe specificity when applied to neurons shortly after plating, DIV 
1-2 neurons will be treated with nanoprobe in conjunction with the non-NMDAR 
glutamate receptor antagonist DNQX, and again without the presence of DNQX.  
Coverslips of DIV 1-2 neurons will be washed with ECS, treated with 10 μM DNQX 
in conjunction with 300 nM nanoprobe, washed again, imaged, treated with 300 nM 
nanoprobe alone, washed and imaged again. Fluorescent labeling of tissue treated 
with nanoprobe alone will be compared to labeling in the presence of DNQX. 
Tracking movements of nanoprobe-labeled receptors in young 
and maturing cultures 
One of the motivations for the development of a traceless, chemical-based method to 
label CP-AMPARs was to observe minimally perturbed receptor movements in live 
neurons. To visualize labeling and trafficking of endogenous receptors on live neurons, 
we will record time-lapse images of live neurons labeled with nanoprobe. Coverslips 
of DIV 14-17 neurons will be washed with ECS, incubated with 300 nM nanoprobe for 
5 min in the dark, exposed to 405 nm light for photolysis of the nitroindoline, washed 
again, and imaged to compile a time-series. To visualize trafficking of CP-AMPARs in 
earlier stages of neuron development, we will follow the same washing and labeling 




Co-incubation with mitochondrial label 
To determine if nanoprobe labeling overlaps with mitochondrial locations in DIV 1-2 
neurons, coverslips will be co-treated with both nanoprobe and the mitochondrial label 
MitoTracker Green FM from Cell Signaling Technology. The neurons will be washed 
with ECS, treated with nanoprobe and washed again, then incubated with 500 nM 






Aim 1: Whole cell patch clamp electrophysiology  
The goal of aim 1 is to use whole cell patch clamp electrophysiology to test the labeling 
of CP-AMPARs with nanoprobe by recording changes in glutamate-evoked current 
through heterologously expressed GluA1-L497Y homomultimers during, pre- and 
post- nanoprobe labeling.  
If the nanoprobe behaves as an open-channel blocker as designed, I would predict that 
during the treatment with glutamate and nanoprobe together there will be a loss of 
current as the nanoprobe ligand enters the open channels and blocks ion flow (Figure 
6). Once the nanoprobe ligand has entered a channel, it should bring the electrophilic 
arm of the probe into proximity with nucleophiles on the surface of the receptor, 
leading to a covalent interaction that anchors the nanoprobe within the ion channel. 
I would expect this to be demonstrated by a continued channel block even after excess 
nanoprobe has been washed away and a new pulse of glutamate has been delivered to 
re-open the channels. Finally, if the ligand is photocleavable as expected, the 
application of UV light should cleave the ligand from the rest of the molecule, allowing 
the ligand to wash away. Without ligand blocking the channels glutamate-evoked 
current should be restored (Figure 6), which I would expect following application of 
UV light in conjunction with glutamate. 
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In contrast, when nanoprobe alone is applied to a patched cell, I would predict that 
glutamate-evoked responses following nanoprobe treatment will be the same as the 
pre-treatment glutamate pulses. Nanoprobe ligand should be unable to enter the 
channels of inactive CP-AMPARS, so I would expect the nanoprobe to simply remain 
in the bath until washed away, after which the channels should open in response to 
glutamate and pass ionic current as they normally would (Figure 5). 
Aim 2: Imaging co-labeled endogenous receptors  
The goal of aim 2 is to use fluorescent imaging to evaluate nanoprobe labeling of 
glutamate receptors endogenously expressed in hippocampal neurons by co-labeling 
nanoprobe-treated neurons with traditional antibodies to AMPAR and synaptic 
targets.  
If nanoprobe labels CP-AMPARs as it is designed to do, I would expect nanoprobe to 
largely colocalize with pan-AMPAR and GluA1 antibodies, as both antibodies will 
target all AMPARs, including CP-AMPARs. As these antibodies should label all 
calcium-impermeable AMPARs too, I would expect a large population of receptors to 
be labeled with antibody but not co-labeled by nanoprobe. I would also expect to see 
some overlap between nanoprobe labeling and the antibody for the pre-synaptic 
protein synapsin-1, though again I would expect the antibody labeling to be much 
more widespread than nanoprobe labeling, as synapsin-1 is found at both 
glutamatergic and GABAergic synapses. Synapses expressing CP-AMPARs would 
only be a small subset of all synapses labeled by anti-synapsin 1.  
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The pharmacological treatments (glutamate, DNQX) applied in conjunction with 
nanoprobe should alter the amount of probe that colocalizes with AMPAR and 
synapsin antibodies, as well as the total amount of probe labeling visible on treated 
neurons. When neurons are treated with nanoprobe alone, I would expect to see 
labeling only at active synapses, as availability of glutamate-bound CP-AMPARs 
would be restricted to those sites. A global treatment of glutamate would theoretically 
make all surface-expressed CP-AMPARs available for nanoprobe labeling, resulting 
in more abundant probe labeling and more colocalization with anti-AMPAR 
antibodies. Thus, following co-application of glutamate and nanoprobe to neurons, I 
would expect to see more widespread nanoprobe labeling of CP-AMPARs at active 
synapses and CP-AMPARs at extrasynaptic sites. In contrast, I would expect neurons 
treated with DNQX and nanoprobe together to have reduced probe labeling. DNQX 
blocks the glutamate-binding site of non-NMDAR glutamate receptors, which should 
prevent CP-AMPARs from binding glutamate and thus reduce the number of CP-
AMPARs with open ion channels available for interaction with nanoprobe.  
As non-liganded nanoprobe lacks the NASPM-derived ligand to enable specific 
interaction with CP-AMPARs, I would expect neurons treated with this compound to 
have greatly reduced fluorescent labeling when compared to neurons treated with 
fully liganded probe. There may be some labeling as a result of interactions between 
non-CP-AMPAR nucleophiles on the cell membrane and the electrophile on the non-




Aim 3: Imaging and tracking nanoprobe-labeled receptors 
on live neurons 
The goal of aim 3 is to use nanoprobe to detect endogenously expressed CP-AMPARs 
during the course of neuron development. Live neuronal cultures will be imaged before 
and after labeling with nanoprobe in young dissociated cultures (DIV 1-2) and in 
maturing cultures (DIV 14-17). 
If nanoprobe labels CP-AMPARs in live neuronal culture as expected, I predict an 
increase in punctate fluorescent labeling on a subset of neurons following treatment 
with probe. Given that the reported range of IC50 values for this pharmacological class 
is 30 nM to 3 µM (Brackley et al., 1993; Jackson et al., 2011), I would expect effective 
labeling to occur somewhere within this range, likely on the low end. While the IC50 
values for polyamine toxins at CP-AMPARs and other receptors are covered in greater 
depth in the introduction, most significantly Koike et al. (1997) found an IC50 of 0.33 
μM for NASPM blockage of CP-AMPARs. As nanoprobe ligand is derived from 
NASPM, I would expect the probe molecule to have a similar IC50, suggesting that a 
dose in the range of 300 nM to 1 µM should be sufficient to effectively label a majority 
of CP-AMPARs.  
As discussed in the introduction, CP-AMPARs are known to be involved in some forms 
of synaptic plasticity, and to be abundant on some neurons in early stages of 
development. Thus I would expect to see labeling on both older, synaptically active 
neurons undergoing spinogenesis (DIV 14-17) and on younger neurons shortly after 
plating (DIV 1-2). Glutamate receptors are trafficked to sites of active plasticity 
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(Kessels & Malinow, 2009; Malenka & Bear, 2004) so I would expect to see a detectable 
level of trafficking in older neurons undergoing spinogenesis both via local lateral 
diffusion and intracellular vesicular trafficking (Chater & Goda, 2014; Washbourne 
et al., 2002). Following co-treatment with competitor molecules NASPM or DNQX I 
would expect to see a reduction in punctate labeling due to competition for the open 






Aim 1: Whole cell patch clamp electrophysiology  
The goal of aim 1 was to use whole cell patch clamp electrophysiology to test the 
labeling of CP-AMPARs with nanoprobe by recording changes in glutamate-evoked 
current through heterologously expressed GluA1-L497Y homomultimers during, pre- 
and post- nanoprobe labeling. 
Nanoprobe is designed to target active CP-AMPARs via a ligand derived from the open 
channel blocker NASPM. For the intrinsic ion channel of the CP-AMPAR to be 
available for interaction with NASPM, the receptor must bind an agonist to initiate 
opening of the ion channel (Figure 2). To evaluate nanoprobe labeling of functional, 
active CP-AMPARs we applied nanoprobe to heterologously expressed GluA1 
homomultimers, both in conjunction with glutamate and without glutamate present, 
and measured glutamate-evoked current with whole cell patch clamp 
electrophysiology. We found that 1 μM nanoprobe in conjunction with 20 μM 
glutamate blocks approximately 60% of the glutamate-evoked current through active 
GluA1 homomultimers (n=10, Figure 7). This is in keeping with the finding by Koike 
et al. (1997) that 1 μM NASPM blocked approximately 70% of agonist-evoked current, 
suggesting that nanoprobe ligand acts as an activity-dependent channel-blocker in a 
similar manner to NASPM. In contrast, following application of  1 μM nanoprobe 
alone, only about 20% of glutamate-evoked current is blocked (n=6, Figure 7). This 
partial block may be due to residual nanoprobe in the bath. Or, over the course of the 
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1 minute nanoprobe incubation, stochastic channel opening may have made some ion 
channels available for interaction with probe ligand even in the absence of glutamate, 
allowing for some channels to be blocked. These results suggest that nanoprobe does 
indeed label active CP-AMPARs preferentially, supporting the supposition that 
nanoprobe will target CP-AMPARs at excitatory synapses where glutamate is being 
released.   
Nanoprobe is also designed to be a minimally perturbing CP-AMPAR label, with a 
ligand that can be removed to relieve open-channel block of the targeted receptor after 
labeling. The NASPM-derived ligand is connected to the rest of the probe molecule via 
a photocleavable linker so that it can be cleaved with UV light after bringing the 
electrophilic moiety into contact with a receptor (Figure 3). Once the electrophile has 
covalently bound to a nucleophile on the receptor surface, the probe fluorophore will 
remain attached to the receptor after ligand removal. To evaluate the effectiveness of 
photolytic ligand release and removal of CP-AMPAR channel block, glutamate-
induced current was probed twice with 1 second pulses of glutamate after the 
nanoprobe/glutamate treatment. The first glutamate pulse was delivered alone, and 
the second in conjunction with a 15 second exposure to 380 nm light, which relieved a 
significant portion of nanoprobe-induced open channel block (Figure 7). Full 
glutamate-response was restored after an ECS wash. This finding is consistent with 
the expectation that ligand is cleaved upon exposure to UV light, unblocking receptor 
channels and restoring normal glutamate-evoked current into the cell. 
Figure 7 (Vytla et al., 2011) depicts and summarizes the electrophysiological data 
from HEK293T cells heterologously expressing GluA1-L497Y homomers, patched in 
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whole cell patch clamp configuration. Parts A and B are representative recordings 
from single cells treated with either glutamate and nanoprobe together (A), or 
nanoprobe alone (B). These recordings demonstrate the activity-dependent nature of 
the nanoprobe interaction with CP-AMPARs, and the photolytic release of ligand. In 
part A, one of three baseline glutamate-responses is shown, followed by 1 minute of 
glutamate and nanoprobe perfusion, and then 1 minute of ECS perfusion to remove 
any remaining nanoprobe. A 1 second pulse of glutamate was then delivered to probe 
the ability of the CP-AMPARs to open in response to glutamate. Fifteen seconds later, 
another 1 sec pulse of glutamate was delivered in combination with a 15 second 
exposure to UV light, restoring much of the glutamate-evoked current. The initial 
remaining partial block is likely due to residual ligand present in the bath after 
photocleavage, as after a 30 second ECS wash, glutamate-evoked currents were 
restored to normal magnitude. In contrast, cells treated with nanoprobe alone show 
little reduction in glutamate response even prior to application of UV light (B).    
Part C summarizes and quantifies the change in peak glutamate-evoked current 
following treatment with either nanoprobe alone, or nanoprobe and glutamate 
together, before and after photolytic release of the ligand. For each treatment 
condition the white column represents normalized peak current in response to the 
first glutamate test pulse, and the purple column represents normalized peak current 
in response to the second glutamate test pulse, delivered in combination with UV 
light. For each cell, peak glutamate currents were normalized to the cell’s baseline 
glutamate response. Prior to treatment, a baseline response to glutamate was 
measured using three 1 second pulses of 20 μM glutamate, each delivered 1 minute 
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apart with ongoing ECS perfusion between each pulse. The average peak current for 
all three of these glutamate responses provides a baseline reference to which 
subsequent glutamate responses were normalized.  
The evidence gathered from these electrophysiological experiments suggests that 
nanoprobe acts as a minimally perturbing label of active CP-AMPARs. Experimental 
results show that nanoprobe preferentially targets active, glutamate bound CP-
AMPARs over inactive receptors, acting as an open channel blocker as expected. 
Furthermore, photolytic release of the ligand followed by ECS perfusion relieves 
channel block and restores normal glutamate-evoked response, indicating that the 
ligand is being successfully cleaved with UV light, returning the receptor to a normal 
gating state. Taken together, these results suggest that nanoprobe will label CP-
AMPARs at glutamatergic synapses in a minimally-perturbing fashion that allows 







Aim 2: Imaging co-labeled endogenous receptors  
The goal of aim 2 was to use fluorescent imaging to evaluate nanoprobe labeling of 
glutamate receptors endogenously expressed in hippocampal neurons by co-labeling 
nanoprobe-treated neurons with traditional antibodies to AMPAR and synaptic 
targets.  
As a first step towards visualizing nanoprobe labeling of neuronal receptors we 
imaged live neurons before and after nanoprobe treatments. Neuronal cultures were 
imaged prior to treatment, washed, incubated with nanoprobe, washed again, and re-
imaged to visualize fluorescent labeling. The goal of these early labeling experiments 
was to determine appropriate concentrations and incubation times for nanoprobe 
imaging experiments. Initial results indicated that replacing the dansyl fluorophore 
with a different fluorescent tag might make nanoprobe labeling easier to visualize.  
The initial version of nanoprobe, synthesized by Dr. Vytla Devaiah, employed dansyl 
as the fluorophore that would remain covalently attached to the target protein after 
ligand-removal. Dansyl is excited by UV light and emits maximum fluorescence 
intensity in the range of 500 nm. Peak emission is affected by polarity and pH 
(Holmes-Farley & Whitesides, 1985), making dansyl a possible candidate for reporting 
on the receptor environment by tracking changes in peak emission wavelength. The 
ligand-binding domain of AMPA receptors changes shape when transitioning from an 
apo to an agonist-bound state, and again to a desensitized state (Traynelis et al., 
2010). Depending on the precise location of where the fluorophore was bound to a 
receptor surface, these conformation changes could potentially alter the pH and 
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polarity of the fluorophore’s local environment to provide a visual signal of the 
receptor’s current state. 
Early attempts to image dansyl-nanoprobe were hampered by difficulties in detecting 
the fluorophore signal above high levels of background autofluorescence. Several of 
the primary sources of endogenous autofluorescence in cell culture are excited in the 
UV range and fluoresce in a broad spectrum overlapping with the dansyl emission 
spectrum, including NAD(P)H, flavins, and lipofuscin (Monici, 2005). This fact coupled 
with the low extinction coefficient of the dansyl fluorophore frequently meant that 
nanoprobe labeling was hidden by the overall brightness of the tissue 
autofluorescence in culture. We had some success using a 100 µM concentration of 
nanoprobe, which produced punctate labeling along neurites when compared with 
background fluorescence in extracellular solution (Figure 8), though this labeling was 
only distinguishable in regions with few neuronal cell bodies and little to no glia 






Figure 9 shows the fluorescence intensity graphed for selected regions of the neurites 
pictured in Figure 8 before and after treatment with nanoprobe. The fluorescence is 
suggestive of a pattern of labeled, spine-like puncta strung along dendrites. However, 
at such a high concentration of nanoprobe the likelihood of non-specific labeling 
increases. As previously discussed, to achieve CP-AMPAR specificity the ligand 
portion of the probe was designed to capitalize on the pharmacology of the polyamine 
toxin molecules Joro spider toxin, argiotoxin, philanthotoxin-433 and, most 
structurally similar, the synthetic CP-AMPAR blocker NASPM (Brackley et al., 1993; 
Stromgaard et al., 1999; Stromgaard & Mellor, 2004; Yoneda et al., 2001). Each one 
of these molecules has been used previously to specifically target and block CP-
AMPARs.  However, some of these toxins have also been used to target CP-kainate 
receptors, NMDA receptors, and even to block nAChRs at high concentrations 
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(Bahring & Mayer, 1998; Brackley et al., 1993; Mellor et al., 2003; Ogoshi & Weiss, 
2003; Stromgaard & Mellor, 2004; Sun et al., 2009; Yin et al., 2002). A more in-depth 
discussion of the interactions between these toxins and polyamine sensitive receptors 
can be found in the introduction.  
Due to these potential off-target interactions it is important to use a concentration of 
nanoprobe within a reasonable range for targeting CP-AMPARs specifically. However, 
determining an accurate IC50 value for this pharmacological class has been the subject 
of some effort due to differences in reported neuronal preparation and experimental 
conditions. Variations in these conditions such as age of preparation, use of intact 
versus dissociated tissue, and concentration of agent, as well as the use-dependency 
and voltage-sensitivity of antagonism that these molecules exhibit have contributed 
to a broad range in reported efficacy. As previously mentioned, IC50 values from 
literature reports for this class of blockers range from 30 nM to 3 µM (Brackley et al., 
1993; Jackson et al., 2011). While this might make it difficult to optimize 
concentration, it is clear that ultimately 100 µM is much too high of a concentration 
to be considered specific to CP-AMPARs, making the results of this labeling 
interesting but far from conclusive 
To address some of these complications a new version of nanoprobe was synthesized 
by Dr. Devaiah, using Cy3 to replace dansyl as the fluorophore. Cy3 has a much higher 
extinction coefficient (Gruber et al., 2000) and an excitation maximum in the visible 
spectrum, at  550 nm, red-shifted away from some of the peak excitation wavelengths 
for the endogenous autofluorescent compounds. This change was implemented in 
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hopes that these more bioimaging compatible Cy3 properties would improve visibility 
of the fluorescent tag against the background. 
After further experimentation with nanoprobe concentration, hippocampal cells were 
cultured, treated with 5 µM of the new Cy3-nanoprobe, and then fixed and stained 
with the monoclonal anti-GluR1-NT clone RH 95 (MAB2263) antibody from Millipore, 
an antibody for the GluA1 subunit of AMPA receptors, targeted to the extracellular 
amino-terminus. GluA1 is incorporated into both calcium-permeable and non-
calcium-permeable AMPARs, so we expected that most nanoprobe labeling would 
colocalize with GluA1, while anti-GluA1 would label many additional non-CP-
AMPARs as well. Slides were imaged using confocal microscopy (Figure 10). We found 
punctate Cy3 labeling visible on some neurons in a pattern resembling dendritic 
spines, but we were surprised by the general lack of overlap between nanoprobe and 
antibody labeling. We hypothesized that a portion of the receptors labeled by 
nanoprobe had been internalized as a result of the temporary blockage of the channel 
pores during the 2 minute incubation with the probe. Anti-GluA1 would not have 
reached these internalized receptors as cell membranes were not permeabilized 
during antibody labeling, in which case the lack of overlap between the two tagged 










As 5 µM of nanoprobe is still above the 30 nM to 3 µM  IC50 range of polyamine toxins, 
leaving the receptor specificity uncertain, we shifted to using lower concentrations of 
nanoprobe to compare probe labeling with GluA1-labeling. DIV 21 dissociated 
hippocampal cultures were incubated with 250 nM Cy3-nanoprobe for 2 minutes, 
fixed, and again labeled with the GluA1 antibody at a 1:1000 dilution. This time cell 
membranes were permeabilized during antibody application to allow for antibody-




widely clustered in puncta on somas and neurites as would be expected due to the 
prevalence of GluA1 subunit. In the center of some of these puncta we found smaller 
yellow clusters indicating potential overlap with the Cy3 label (Figures 11 and 12). 
We were intrigued by these results as they suggested that there could be central 
populations of CP-AMARs within some dendrites, however the widespread red 
autofluorescence in the background called into question whether these yellow clusters 
indicated actual receptor overlap or merely autofluorescence in the red channel. 
Cultures treated with higher concentrations of Cy3-nanoprobe, ranging from 500 nM 
to 1 µM, fixed, and stained with anti-GluA1 primarily seemed to have an increase in 
red background ‘speckling’ making it harder to distinguish genuine labeling from 
background or off-target fluorescence. Increasing the concentration back up to 5 µM 
also seemed to primarily increase background without improving the colocalization of 
nanoprobe and antibody, though cell membranes were still being permeabilized as 
part of the antibody staining process. Throughout this process imaging parameters 
were experimented with in attempts to enhance the distinction between labeled 
receptors and background, including exposure times, z-stack slice sizes, and averaging 
multiple scans together in hopes that fluorescence at receptor clusters would be more 
concentrated and thus persist more clearly than background fluorescence. Varying the 
number of washes applied pre- and post- treatment with probe did not seem to 




To further elucidate probe distribution on labeled neurons, coverslips of DIV 16 to DIV 
21 dissociated hippocampal culture were treated for 1-2 minutes with 250 nM, 500 
nM, 750 nM or 1 µM nanoprobe, either alone or in conjunction with 25 µM of the 
AMPAR antagonist DNQX. Coverslips were then fixed and stained with anti-GluA1 
antibody in hopes that comparison of these treatments would provide some clear 
distinction in the labeling patterns. This was not the case however. The overlap 
coefficient between probe fluorescence and antibody fluorescence as determined by the 
Zeiss LSM software ranged from 0.2 to 0.6 for treatments with nanoprobe and DNQX 
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combined. For coverslips treated with nanoprobe alone, overlap coefficients ranged 
from 0.2 to 0.7 at the upper end.  
An overlap coefficient of 1 would indicate nanoprobe labeling perfectly overlapped 
with antibody labeling. If there were distinct differences between probe labeling of 
CP-AMPARs treated with nanoprobe alone and CP-AMPARS treated with DNQX and 
probe together, we would expect to consistently see an overlap coefficient closer to 1 
for the nanoprobe alone condition, and a consistently smaller coefficient for the  
DNQX/probe combination, indicating less overlap between probe and antibody label. 
Given the range of overlap coefficients for the DNQX control competition condition 




clear pattern seems to be emerging. Interestingly, in probe alone applications, higher 
nanoprobe concentrations did not correlate to higher overlap coefficients, suggesting 
that the lowest dose for targeting CP-AMPARs is at least equally effective as higher 
doses. The neuron on which the most apparent probe/antibody overlap was found was 
from a coverslip treated with 250 nM nanoprobe for 2 minutes. However, a closer look 
calls into question the significance of all of these overlap measurements. When hand-
selected ROIs and background regions were compared, the difference between label 
overlap on a neurite of interest and label overlap on a selected region of nearby 
background was only ~0.1, indicating that overall measured overlap might be as much 
due to background fluorescence as colocalization on actual neuronal structures.  
Initially we expected that as a majority of hippocampal AMPARs contain the GluA1 
subunit (Lu et al., 2009), we should see both abundant GluA1-labeling, and nanoprobe 
labeled-receptors largely colocalized with the GluA1 label. However, while GluA1-




Perhaps the placement of the nanoprobe itself on the receptors interferes with the 
antibody recognition of its target by disrupting binding interactions with a key residue 
(Janeway et al., 2001), or perhaps under our culture conditions the number of CP-
AMPARs expressed is too small to be readily visible above background. As a point of 
comparison we also co-treated neurons with nanoprobe and a polyclonal pan-AMPAR 
antibody for labeling all AMPA receptors. An example is shown in Figure 13. However, 
these experiments also failed to reveal clear receptor labeling, with background 
fluorescence seeming to be brighter than any synaptic or receptor labeling. Out of all 
of these attempts using anti-GluA1 and pan-AMPAR antibody to demonstrate co-
labeling of receptors, while colocalization between nanoprobe and antibody seemed 
minimal, when we did manage to image what appeared to be true nanoprobe labeling 
of receptors on neurites at levels well above background fluorescence, the pattern of 
fluorescence was punctate along neurites and soma as would be expected if labeling 
dendrites (Figure 10).  
To colocalize nanoprobe with an antibody targeted to something other than AMPARS 
themselves, and to visualize the proximity of nanoprobe-labeled receptors to synapses, 
we treated neurons with probe and then stained them with an antibody for a pre-
synaptic protein. DIV 23 neurons were treated with 200 nM nanoprobe for 1, 2 or 5 
minutes, either alone or in conjunction with 20 µM glutamate, fixed, and stained for 
the pre-synaptic protein synapsin-1 using a 488 secondary antibody. The Cell 
Signaling synapsin-1 (D12G5) XP #5297 monoclonal antibody was used at a 1:500 
dilution, with a permeabilizing blocking buffer. Coverslips were imaged using a 
spinning disk confocal microscope. By treating cultures for a variety of times, we 
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hoped to gain a clearer picture of whether receptors were being internalized after a 
certain period of time incubating with nanoprobe.  
After selecting images that appeared to have the most distinct nanoprobe labeling, 5 
fields of view treated with nanoprobe alone and 4 treated with glutamate and 
nanoprobe together were analyzed for colocalization. Sites of synapsin staining were 
identified and used to determine ROIs, then analyzed for overlap with nanoprobe 
labeling. On coverslips treated with nanoprobe alone, out of 1207 synapsin-stained 
ROIs we found 46 (3.81%) that were also labeled with nanoprobe. For coverslips 




59 (8.95%) were co-labeled with nanoprobe. As indicated by the low colocalization 
values most neurons in both treatment conditions had very little overlap of synapsin 
and nanoprobe staining (Figure 15), though one notable neuron had nearly fifty 
percent colocalization (Figure 14). After both treatment conditions the overall 
nanoprobe staining intensity was typically low compared to background intensity, 
with the exception of the neuron that showed such extensive colocalization. Finding 
an example of punctate nanoprobe labeling with a high percentage of overlap with 
synapsin-1 labeling could suggest that the apparent overall low level nanoprobe 
labeling found in our fixed cells is due to a general lack of CP-AMPAR expressing 
neurons in our DIV 20-23 dissociated cultures.  
As a point of comparison, untreated neurons were washed with ECS, fixed and imaged 
using the same acquisition settings as those used for coverslips co-labeled with 
nanoprobe and synapsin (Figure 16). Brightness settings were adjusted to be the same 
as those used to visualize probe labeling in Figures 14 and 15, and though these 
neurons were untreated with nanoprobe, they displayed comparable levels of red 
fluorescence to nanoprobe-treated neurons. Given these results it seems that red 





Ongoing attempts to visualize nanoprobe labeling on fixed dissociated neuronal 
cultures has produced little in the way of clear, consistent punctate labeling. To 
visualize nanoprobe staining on fixed cells without antibody present, DIV 22 cultures 




periods of 10 seconds, 1 minute and 10 minutes to evaluate the effectiveness of 
nanoprobe at different concentrations and for different periods of labeling. Five 
regions on each coverslip were randomly selected and imaged using the 561 laser of a 
spinning disk confocal microscope, 40 slices per image separated by 0.2 µm 
increments. While the highest concentration of nanoprobe showed a stronger overall 
fluorescence intensity, no combination of treatments consistently generated any kind 
of labeling that could clearly be distinguished as separate from 
background/autofluorescence. Representative images from coverslips treated for 1 
minute with varying probe concentrations can be seen in Figure 17 
As a follow-up, DIV 19 dissociated neurons were labeled with 30 nM, 100 nM, 300 nM, 
and 3 µM  nanoprobe either in combination with 20 µM glutamate or with nanoprobe 
alone for incubation periods of 10 seconds, 1 minute and 10 minutes to determine if 
the inclusion of glutamate would establish clearer labeling patterns. Again, 5 regions 
on each coverslip were selected, this time using the bright-field view to locate clearly 
visible, healthy-looking neurons. Coverslips were again imaged using the 561 laser of 
a spinning disk confocal microscope (Figure 18). Red fluorescence appeared to be more 
concentrated in clusters within cells in a manner consistent with receptor 
internalization, as compared to the often more diffuse red fluorescence seen in cells 
treated with nanoprobe alone. AMPAR endocytosis can increase in response to 
glutamate application (Carroll et al., 2001; Lissin et al., 1999) so this pattern could be 
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After extensive attempts to image nanoprobe colocalization with fluorescent 
antibodies to AMPAR and synaptic targets, it was rare to find clear examples of 
receptors or synapses co-labeled with both nanoprobe and antibody. The original 
dansyl fluorophore was replaced with Cy3 to reduce autofluorescence. Nanoprobe 
concentrations and incubation periods were varied to reduce possible off-target 
interactions and to avoid potential receptor internalization, and during antibody 
application membranes were permeabilized to allow antibody access to endocytosed 
receptors. Even given these variations, there appeared to be little overlap between 
nanoprobe and antibody labeling, apart for one very notable exception (Figure 14), 
and possibly Figures 11 and 12. Occasionally there were examples of what appeared 
to be punctate nanoprobe labeling that did not overlap with antibody labeling (Figure 
10). However, when untreated neurons were fixed, imaged, and visualized using the 
same parameters as those used for imaging and visualizing nanoprobe-labeling, 
significant red autofluorescence was present (Figure 16). Taken all together these 
results suggest that we may be capturing some true nanoprobe-labeling, but that 
autofluorescence may be masking too much of it for the images to be useful. Or 
perhaps low CP-AMPAR expression has made it difficult to locate true examples of 
nanoprobe-labeling. Perhaps off-target labeling has led to red fluorescence where 
there should be none, though given the significant amount of red autofluorescence 
present in totally untreated neurons, off-target labeling is not required to explain 
extensive background/autofluorescence.  
Overall it seems that co-labeling endogenous glutamate receptors on dissociated 
neurons with nanoprobe and fluorescent antibodies targeted to AMPAR and synaptic 
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targets has offered few successful examples of clear co-labeling, with a few interesting 
exceptions or partial exceptions. From these results it remains unclear if nanoprobe 
is largely being obscured by autofluorescence, if CP-AMPAR expression is just really 
low, if nanoprobe is having more off-target interactions than expected, or some 
combination of these three explanations. It does seem that studying fixed and labeled 
cells is an ineffective way to research nanoprobe labeling patterns.  
Aim 3: Imaging and tracking nanoprobe-labeled receptors 
on live neurons 
The goal of aim 3 was to use nanoprobe to detect endogenously expressed CP-AMPARs 
during the course of neuron development. Live neuronal cultures will be imaged before 
and after nanoprobe labeling in young dissociated cultures (DIV 1-2) and in maturing 
cultures (DIV 14-17). 
In live, maturing neuronal cultures (DIV 14-17) we have found that nanoprobe 
application produces abundant fluorescent labeling at putative synaptic spines, and 
that these labeled sites can be observed to undergo local trafficking as well as active 
intracellular transport during the course of minutes, in a manner consistent with 
receptor trafficking. In experiments using younger cultures (DIV 1-2) we have 
visualized labeling of elaborate networks of tubular vesicles which traffic along 
neurites and rapidly move in and out of the soma. Control competition experiments 
demonstrate that the labeled proteins are likely CP-AMPARs, as the majority of 
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labeling is blocked by either competition with NASPM or DNQX in both young and 
mature cultures.   
Dose-dependent labeling of live neurons with nanoprobe  
To determine a useful concentration range for labeling live neurons with nanoprobe, 
coverslips of live DIV 14-17 neurons were washed 3 times with extracellular buffer, 
imaged to establish background fluorescence, and then treated with 100 nM 
nanoprobe in extracellular buffer for 5 minutes. After this incubation period with a 
low concentration of nanoprobe, the coverslips were gently washed 3 times with 
extracellular buffer and imaged again. Finally, the same region of the coverslip was 
used to assay a higher concentration of nanoprobe, independently either 300 nM, 1 
µM, or 3 µM in extracellular buffer. A 5 minute incubation in the higher concentration 
of nanoprobe was followed by 3 washes with extracellular buffer prior to resuming 
imaging (Figure 19). We performed this treatment and imaging regimen so that we 
could compare labeling within a range of concentrations similar to the IC50 reports for 
the pharmacological class on which nanoprobe is based (Brackley et al., 1993; Jackson 
et al., 2011).   
Nanoprobe concentrations of 100 nM were not statistically different from background 
fluorescence on any of the neurons we tested. However, 300 nM nanoprobe resulted 
in an increase in fluorescence, with accumulations of peak brightness on neurites in 
a punctate pattern that typically appeared to be located at synaptic spines as judged 
by bright-field morphology. Use of nanoprobe concentrations of 1 µM or 3 µM 
demonstrated a marked increase in accumulated fluorescence, however some of this 
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labeling appeared to be non-specific in nature, particularly at 3 µM. As a 5 minute 
incubation of 300 nM nanoprobe sufficed for robust labeling (Figure 19) of punctate 
areas on neurites, treatments of 300 nM nanoprobe were used for subsequent labeling 
of live neuronal cultures.   
Nanoprobe labeling of live neurons is prevented by co-
incubation with competitor molecules 
To test nanoprobe specificity for CP-AMPARs under live imaging conditions, probe was 
applied to DIV 14-17 neuronal cultures in conjunction with non-fluorescent competitor 
molecules. Use of live neurons allowed us to image nanoprobe labeling of the same 
neurons under competition conditions and when treated with nanoprobe alone. Each 
coverslip was washed 3 times and imaged to establish background fluorescence before 
application of any treatments. Coverslips were then co-treated with nanoprobe and 
the competitor molecule, washed thoroughly with ECS, imaged, treated with 
nanoprobe alone, and washed and imaged again. NASPM and DNQX were separately 
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evaluated as competitor molecules to nanoprobe, with reduced fluorescent nanoprobe 





Co-incubation with a stoichiometric concentration of NASPM was used to determine 
if the probe molecule was reacting with off-target proteins or if it was targeting the 
same ion conduction pore site as NASPM. We hypothesized that NASPM co-
incubation should block some, but not all, of our probe labeling since the two molecules 
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share the acylated polyamine ligand. Co-incubation of neuronal cultures with a 
combination of 300 nM nanoprobe and 300 nM NASPM resulted in a modest increase 
in fluorescence intensity (18.1% increase) when compared to background fluorescence 
(Figure 19, C). When these same fields of view were treated with 300 nM 
nanoprobe alone, a large increase in fluorescence was observed, indicating that 
NASPM is indeed competing with nanoprobe for binding sites. This peak fluorescence 
generated by nanoprobe treatment alone provided the maximal, normalized 
fluorescence in this experiment, 100%. Since NASPM is a non-covalent binder, we 
expected this stoichiometric competition experiment to result in at least 50% labeling 
of binding sites because nanoprobe should kinetically trap the binding event. NASPM 
is a non-covalent drug whereas nanoprobe forms a covalent bond with no off-rate and 
thus acts as a kinetic trap until photolysis of the nitroindoline releases the ligand. The 
fact that NASPM blocks the majority of the fluorescence accumulation of 
nanoprobe labeling suggests that the binding affinity of NASPM is significantly 
higher than that of nanoprobe. Though the affinity of NASPM for target proteins was 
higher than expected in comparison to nanoprobe, this result still provides evidence 
that NASPM and nanoprobe do compete for the same binding sites as expected 
(Figure 19, C and D). 
To assay the specificity of nanoprobe for AMPA receptors we performed another 
competition experiment, this time with DNQX, a competitive antagonist for the 
glutamate-binding site. Similar to the previously described experiment, after the 
nanoprobe/DNQX co-treatment, coverslips were washed and treated with 300 nM 
nanoprobe alone. The nanoprobe ligand is designed to interact with the intrinsic ion 
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channel conduction pore of CP-AMPARs when the channel is activated. DNQX blocks 
the glutamate-binding site of AMPARs and kainate receptors, and is expected to 
prevent channel opening. Thus, we expected co-incubation with 10 μM DNQX to 
prevent fluorescent labeling with 300 nM nanoprobe. Indeed, when we co-treated DIV 
14–17 neurons with a combination of DNQX and nanoprobe, we found a slight 
increase in fluorescence intensity (13.1% increase) when compared to background 
fluorescence (Figure 19, C.). When we co-treated these same fields of view with 
300 nM nanoprobe alone, we observed a large increase in fluorescence. Again, this 
peak fluorescence provided the maximal, normalized fluorescence in this experiment, 
100%. This marked increase in fluorescence intensity suggests that nanoprobe 
labeling is dependent on probe specificity for glutamate receptors that are sensitive to 
DNQX antagonism. The DNQX data combined with the block of fluorescence 
accumulation demonstrated by co-treatment with NASPM suggest that the target of 
nanoprobe labeling is indeed NASPM-sensitive glutamate receptors, very likely CP-
AMPARs.  
Images were analyzed using ImageJ (U.S. National Institutes of Health, Bethesda, 
MD, USA) (Schneider et al., 2012). To allow for quantification of 
nanoprobe accumulation, regions in the field of view which demonstrated fluorescence 
after nanoprobe application (which occurs either after low dose or after 
pharmacological competition experiment) were identified by applying the Triangle 
threshold, a method to geometrically find the maximal data within the largest 
histogram range (Zack et al., 1977). These thresholded images were used as input for 
particle detection to generate an exhaustive ROI (region of interest) list of all labeled 
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regions in the field of view. These ROIs were then applied to the previous time points 
for quantification of fluorescence during either low dose or competition incubations. 
Fluorescence intensities were quantified using the mean gray value of regions labeled 
with nanoprobe. Fluorescence intensity was then measured at these same regions for 
all previous and following time points. To correct for background fluorescence, three 
background ROIs were drawn where there was an absence of visible cells in the 
corresponding bright-field image. The mean intensity of these areas was used to 
calculate the average background that was then subtracted from the mean gray value 
of ROIs at each time point to determine background fluorescence before treatment, 
fluorescence after treatment with control (competition or low dose) solution, and 
fluorescence after treatment with nanoprobe alone. All brightness and contrast 
settings are equal within groups for comparative images presented in Figure 
19 except in the one case where indicated. Group mean values at each concentration 
(Figure 19, A) or treatment condition (Figure 19, C) were compared to the respective 
control values using a one-way non-parametric Kruskal–Wallis test (Mangiavacchi & 
Wolf, 2004). The significant differences were further analyzed with Dunn's multiple 
comparison test. In all cases, p < 0.05 was considered statistically significant and 
individual p values are provided for each test. Asterisks in the figure represent 
statistically significant differences. The values on the graph are expressed as 




Tracked movements of nanoprobe-labeled receptors: DIV 14-17 
To visualize receptor labeling and trafficking in neuronal cultures, live cells (DIV 14–
17) were washed with extracellular buffer and incubated with 300 nM nanoprobe for 
5 min in the dark, exposed to 405 nm light for photolysis of the nitroindoline, washed 
again, and imaged to compile a time-series. We found numerous examples of both 
stable spots of fluorescence and of receptor clusters that moved either locally or 
comparatively long distances along a neurite and, at times, across the entire field of 
view (Movie S1 is demonstrative of these diverse movements and Movie S2 is a sub-
region of Movie S1 that contains colored lines to demonstrate the detected 
movements). The relatively fast moving clusters of receptors traveling along neurites 
appear to be intracellular and in vesicular packages undergoing active transport 
based on their common movement paths. The velocities of the clustered movements 
that we observed are consistent with intracellular vesicular transport observed in 
normal neurons (Turina et al., 2011). Vesicular packages of AMPA receptors have 
been reported elsewhere, and the movements we observe here closely resemble the 
trafficking that others have observed for fluorescently-tagged glutamate receptor 
subunits in vesicles (Ju et al., 2004; Washbourne et al., 2002). 
Tracking data from experiments with DIV 14–17 neurons (Figure 20) was generated 
with Matlab using a custom-built particle tracking software package (Pelletier et al., 
2009). To detect the spots that were moving rapidly along neurites as well as those 
that were relatively stationary, we used a feature size of three pixels. Each image in 
the time series was initially filtered to suppress high frequency noise and low 
frequency background variations. The time series images were collected as a series of 
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single z-plane images and thus, particles that move out of focus or into focus during 
the acquisition are either lost midway through tracking or commenced midway 
through tracking (Movie S2 demonstrates the effect of tracks being lost and started 
at different time points). The filtered image was then processed to find local intensity 
maxima, which are then used as estimated positions in integer pixels for the features 
sought. To refine the feature position about each local maximum, an area surrounding 
the estimated position of radius three pixels was extracted from the image, and the 
refined centroid position was used as the center for a second iteration of area 
extraction and centroid determination. This process yielded the final, calculated 
center position in two dimensions with a computed accuracy of 7 nm. To reliably find 
features in the face of photobleaching and consequent signal-to-noise degradation, the 
criteria for minimum integrated signal intensity and average signal intensity for each 
feature were adjusted automatically throughout the time series, following initial 
careful determination of appropriate acceptance criteria. We manually inspected the 
tracked particles toward the end of each time series to be certain we were robustly 
tracking particles that were easily visible. These criteria were then linearly adjusted 
to the initial frames of the time series so that particles with similar properties could 
be tracked in both early and late frames of each time series. Tracking in time can help 
discriminate noise from real features, as noise will typically not be spatially and 
temporally coherent. To define tracks and movements, the features that were found 
were allowed to move a maximum of eight pixels between frames and were required 
to be tracked for a minimum of 15 frames. The tracks were then overlaid onto the 




We found that the labeled receptors in vesicles move at a fairly wide range of mean 
velocities (Figure 20) with two groups appearing from the particle tracking analysis. 
Some of these clusters move very quickly along tracks defined by neurites while others 
remain stationary, appearing to undergo thermal or non-active motion during 
imaging. After quantifying the mean velocity of 930 moving particles from five 
independent time-lapse experiments, we found that the mean end-to-end velocity of 
these clusters is 31.25 nm/s and a mean instantaneous velocity of 132.4 nm/s. The 
end-to-end velocity is a measure of overall movement where the instantaneous 
velocity provides information on the full range of velocity experienced by individual 
particles. 
The observed movements of labeled receptors are consistent with the previously 
reported velocities for trafficking of GluA1 and GluA2 receptor subunits. Our results 
quite closely match previous reports in which fluorescent fusion protein subunits were 
tracked in dissociated cortical cultures at DIV 3–4 (Washbourne et al., 2002) and 
GluA1 and GluA2 subunits tagged with FlAsH or ReAsh were tracked in dissociated 
hippocampal cultures at DIV 8–9 (Ju et al., 2004). As mentioned above, after labeling 
with nanoprobe, we found an average end-to-end velocity of about 31 nm/s, which is 
almost identical to the velocity that Washbourne et al. (2002) observed for GluA1 
clusters uncombined with NR1, and to the velocity that Ju et al. (2004) observed for 
GluA1 and GluA2 clusters. Thus, our observations of very similar intracellular 
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trafficking velocities suggest that our labeling methodology is comparable to more 






In addition to the movement of vesicular-located receptors along neurites, we also 
observed receptors in vesicles being delivered to a putative synaptic spine (Figure 20, 
A and Movie S3). We believe that these labeled receptors were expressed on the 
surface where they were labeled with our probe prior to endocytosis during the 5 min 
incubation period and then recycled. Because the probe does not cross the membrane 
unassisted, we can surmise that these fluorophores are appended to previously 
exposed CP-AMPARs. 
In addition to intracellular movements of labeled receptors, we have also observed 
that areas of strong nanoprobe labeling can be found to migrate locally in response to 
excitatory stimuli. In some cases, during global bath application of glutamate to 
nanoprobe-labeled neurons, we observed the movement of labeled receptors into 
putative synaptic spines (Figure 21, A and B). It would be interesting to carry out 
further study of this effect in acute slices where synapse organization is more 




Tracked movements of nanoprobe-labeled receptors: DIV 1-2 
To visualize receptor locations earlier in neuronal development, live cells were treated 
with nanoprobe within 1 to 2 days of plating. DIV 1–2 neuronal cultures were washed 
with ECS and incubated with 300 nM nanoprobe for 5 minutes, washed again, and 
imaged to compile a time-series. In contrast to the punctate labeling patterns found 
in older cells treated with nanoprobe, in DIV 1-2 cells labeled with nanoprobe we found 
intricate networks of fluorescent tubular vesicles traveling along neurites, and in and 
out of the soma (Figure 22, Movies S4 and S5). Additionally, often a concentration of 
fluorescence appeared to be gathered internally, on one side of the soma. Based on 





Network (TGN) (Horton et al., 2005), while the tubular vesicles themselves appeared 
similar to mitochondria (Kramer & Enquist, 2012). 
As discussed in the introduction, CP-AMPARs are known to be widely expressed in 
early stages of neuron development. The amount of fluorescent labeling was more 
widespread than expected, though, leading us to wonder if it could be due to some sort 
of non-specific interaction, independent of nanoprobe binding to CP-AMPARS. 





fluorescence was largely dependent on NASPM-sensitive glutamate receptor activity. 
When nanoprobe treatment was paired with NASPM or DNQX, fluorescent labeling 
was greatly reduced compared to follow-up images of the same fields of view after 
treatment with nanoprobe alone. Representative examples can be seen in Figures 20 
and 21.  
 
Due to the visual similarity between the labeled tubular vesicles and neuronal 
mitochondria (Stommel et al., 2007) preliminary experiments were conducted in 
which coverslips of dissociated hippocampal DIV 1-2 neurons were co-treated with 
both nanoprobe and the mitochondrial label MitoTracker Green FM from Cell 
Signaling Technology to determine if both fluorophores labeled the same structures. 
Coverslips were washed 3 times with ECS, incubated with 300 nM nanoprobe for 5 
minutes, washed 3 times again, incubated with 500 nM MitoTracker for 1 minute, 
washed a final time with ECS and imaged. In cells labeled with nanoprobe, nearly 
every structure labeled with probe appeared to be co-labeled with MitoTracker, 
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including tubules (Figures 25-27). However, many cells were labeled with 
MitoTracker that had no nanoprobe labeling whatsoever, reinforcing the idea that 
though the nanoprobe labeling was abundant in certain DIV 1-2 cells, it was still cell-
specific (Figure 26). This specificity, combined with an apparent dependence on active 
glutamate receptors as suggested by the early DNQX and NASPM experiments 
supports the possibility that the labeling of young neurons with nanoprobe still 
depends on CP-AMPAR expression.  
However, if these are CP-AMPARs being expressed and labeled by nanoprobe, they 
seem to have largely been internalized and possibly packaged with mitochondria or 
other dynamic tubules to be carried away on normal vesicular routes. It is known that 
mitochondria linger near synapses where high concentrations of calcium aggregate, 
in fact cytosolic calcium is a primary regulator of mitochondrial movement. Increased 
cytosolic calcium due to a variety of sources, including Ca2+ influx through ionotropic 
glutamate receptors, halts both anterograde and retrograde mitochondrial movement 
(Macaskill et al., 2009; Schwarz, 2013). It is believed that mitochondria are regulated 
in this way so that they can act as calcium buffers in regions of excess calcium, and as 
a source of ATP for active transport of calcium from the cell. Given this putative role 
of mitochondria in managing excess calcium, it seems plausible that they would 
‘linger’ near surface-expressed CP-AMPARs, which, if active, would presumably be 
allowing Ca2+ to influx into the neurons. This does not clarify why these receptors 
would be internalized and ‘packaged’ with mitochondria for transport, other than that 
the mitochondria were located nearby. 
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It would be interesting to more fully explore the apparent CP-AMPAR activity in DIV 
1-2 neurons, we certainly weren’t expecting them to be trafficked so robustly, 
apparently along-side mitochondria. Given more time, it would be interesting to 
attempt to fix and stain DIV 1-2 nanoprobe-treated neurons with antibodies to various 
endosomal compartments, to track the progress of nanoprobe-labeled receptors. 
Endocytosis is often conceptualized as a uni-directional pathway starting with the 
intake of cargo molecules from the plasma membrane, which are then trafficked either 
to the site where the cargo is needed, or to lysosomes for degradation. However, 
endocytic trafficking patterns are frequently more complex and can even involve 
transport directly to and from the TGN, which is typically thought of solely in terms 
of its role in the secretory pathway. Cargo designated for destruction can be trafficked  
to lysosomes via late endosomes, while cargo being returned to the surface may be re-
inserted directly back into the plasma membrane from the early endosome that 
initially engulfed it. Cargos designated for insertion/return to other regions of plasma 
membrane may be carried in recycling endosomes and “tubular intermediates”, and 
as mentioned earlier cargoes may be transported from endosomes to the TGN or 
directly from the TGN to endosomes without insertion into the plasma membrane first  
(Yap & Winckler, 2012). Further complicating matters, in polarized cells such as 
neurons, the TGN plays a role in polarized sorting of cargoes to the somatodendritic 
membrane or the axonal membrane. Proteins may be directly trafficked to the correct 
location from the TGN, trafficked via endosomes, or inserted into the non-target 
membrane domain and then endocytosed and trafficked to the correct domain via a 
process called transcytosis (Yap & Winckler, 2012). Given this, newly plated cells (DIV 
1-2) might have higher rates of endocytosis and sorting as they polarize, though it is 
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worth keeping in mind that in the standard E18 dissociated rat hippocampal cultures, 
most plated neurons were polarized prior to dissociation, and they may retain certain 
aspects of that initial polarization (Polleux & Snider, 2010). This could have an impact 
on receptor trafficking as well. 
Overall, we were surprised to observe the relative abundance of labeling when using 
nanoprobe on hippocampal neurons during live imaging experiments, particularly 
given the prior difficulties in identifying probe-labeled receptors on fixed cells. We 
speculated that this finding could suggest that these cells express more CP-AMPARs 
than previously thought, that there are more NASPM targets that are also sensitive 
to DNQX block, or both. Our experiments with labeling endogenous glutamate 
receptors on live dissociated hippocampal neurons with nanoprobe have provided 
supporting evidence that indeed nanoprobe is targeting NASPM-sensitive glutamate 
receptors, as demonstrated by the effectiveness of the NASPM and DNQX blocks to 
probe labeling. CP-AMPARs are the most likely candidate, given the specificity of 
NASPM for CP-AMPARs (Koike et al., 1997), particularly at lower concentrations. 
Furthermore, the trafficking data for older neurons (DIV 14-17) seems to line up well 
with reported GluA1 and GluA2 trafficking data using genetically engineered 
receptors (Ju et al., 2004; Washbourne et al., 2002). This suggests that not only might 
we be able to accurately target a phenotypically-distinct subset of ionotropic 
glutamate receptors, but we might be able to do this in a way that minimizes 
disruptions caused by genetic engineering or large antibodies, as was part of our 
original goal. If we were able to take the next steps of tracking the movement of these 
nanoprobe-labeled receptors over time, particularly in DIV 1-2 neurons, we could 
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potentially learn much more about the sorting and transportation of receptor 
subunits. Perhaps given a sufficient variety of nanoprobe fluorophores, we could 
visualize different ‘waves’ of receptors internalized, mixed and re-expressed, creating 
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